Press Releases

11.12.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented two posters at the ESMO IO 2017 (European Society for Medical Oncology – Immuno Oncology) in Geneva, Switzerland (7 – 10 December...

28.11.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will be represented with two posters at the ESMO IO 2017 (European Society for Medical Oncology – Immuno Oncology) in Geneva, Switzerland (7 –...

09.11.2017

• U.S. investor Global Corporate Finance is providing further capital and acquiring a stake of up to 10% in MOLOGEN • Binding term sheet signed with Chinese company iPharma for the development, manufacture and commercialization of lefitolimod in...

01.11.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) was granted subsidies from the Global Health Innovative Technology (GHIT) Fund amounting to US$ 2.6 million.

13.09.2017

- Oral presentation of top-line IMPULSE data including invited expert discussion - Poster presentation of new data on lefitolimod as modulator of the tumor microenvironment alone and in combination with immune checkpoint inhibitors in pre-clinical...

05.09.2017

Berlin, 5 September 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present two posters on its lead compound, the immunotherapeutic agent lefitolimod, at the European Society for...

   

Displaying results 1 bis 7 von 20

Page 1

Page 2

Page 3

next

   

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.